Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Roche Could Gain Ground in the Neurodegenerative Drug Market

By Ryan Bushey | February 16, 2017

Roche is poised to become a formidable contender in the neurodegenerative treatment space by 2022, according to a new report from business intelligence provider GBI Research.

Regulatory approval of crenezumab, gantenerumab, and notably ocrevus (ocrelizumab) could give the drug-maker approximately 15 percent of the market share within this forecast period.

The author of the report, GBI analyst Qaisrah Khalid, wrote Ocrevus is expected to become a blockbuster drug within three years of its launch potentially generating $3.2 billion in sales becoming the primary force responsible for Roche’s growth.  

Ocrevus is an investigational monoclonal antibody being tested as a treatment for relapse remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The drug works by targeting CD20-positive B cells that are immune cells which are believed to play a key contributing role in nerve cell damage.

The Food and Drug Administration (FDA) granted Ocrevus a priority review in June 2016 after clinical trial results indicated the six month intravenous injection was able to lower the risk of disability progression by 24 percent in PPMS patients. 

Another study revealed Ocrevus provided better disease control for RRMS patients compared to Merck’s Rebif. A mix of clinical and MRI outcomes were used to test the efficacy of these drugs, but the trial achieved its endpoint when these RRMS patients exhibited no evidence of disease activity over the course of two years.   

RRMS is the most common form of the disease characterized by clearly defined attacks of new or increasing neurologic symptoms followed by periods of partial or complete recovery. Approved treatments for this variation of the disorder include Copaxone, Tecfidera, and Lemtrada.

Ocrevus could fill an important need for patients suffering from PPMS because the rarer but more debilitating form of this condition marked by steadily worsening symptoms has no approved therapy.

However, Khalid’s analysis concludes noting Biogen will maintain its lead over this treatment space throughout the forecast period largely due to Tecfidera sales, which is not set for patent expiry until 2028 while another therapy Plegridy is predicted to reach blockbuster status sometime in the next five years.

The FDA is scheduled to make a decision on Ocrevus in March 2017. The European Medicines Agency will conduct its review of the drug in the third quarter of this year too.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE